Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TRPA1-TRPV1 complex is a functional unit formed by the physical and functional interaction of two members of the transient receptor potential (TRP) superfamily: TRPA1 (Transient Receptor Potential Ankyrin 1) and TRPV1 (Transient Receptor Potential Vanilloid 1). These channels are co-expressed in a subset of primary sensory neurons known as nociceptors, where they can form heteromeric complexes that exhibit distinct biophysical properties compared to their homomeric counterparts (Staruschenko et al., 2010, Journal of Biological Chemistry). The complex plays a critical role in integrating various noxious stimuli, including heat, pungent chemicals (like capsaicin and mustard oil), and inflammatory mediators, thereby serving as a key integrator of pain and inflammatory signals (Patapoutian et al., 2009, Nature Reviews Neuroscience). In disease states, the TRPA1-TRPV1 complex is implicated in the development of chronic pain, hypersensitivity, and neurogenic inflammation, making it a high-priority target for analgesic and anti-inflammatory drug development. Research indicates that the interaction between these channels can modulate their individual sensitivity and trafficking to the plasma membrane, which contributes to the sensitization of nociceptors in conditions like neuropathic pain and asthma (Spahn et al., 2014, Molecular Pain). Pharmacological strategies often involve the use of small molecule antagonists or desensitizing agonists; however, therapeutic development must navigate challenges such as the thermoregulatory side effects associated with TRPV1 modulation and the broad physiological roles of these channels in sensory biology (Julius, 2013, Annual Review of Cell and Developmental Biology).
The complex is targeted via pharmacological antagonism to block ion conductance or through agonist-induced desensitization to reduce the excitability of sensory neurons.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential ankyrin 1 and transient receptor potential vanilloid 1 complex (TRPA1-TRPV1 complex).